These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21672263)

  • 41. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.
    Yan J; Reichenbach DK; Corbitt N; Hokey DA; Ramanathan MP; McKinney KA; Weiner DB; Sewell D
    Vaccine; 2009 Jan; 27(3):431-40. PubMed ID: 19022315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
    Kim D; Gambhira R; Karanam B; Monie A; Hung CF; Roden R; Wu TC
    Vaccine; 2008 Jan; 26(3):351-60. PubMed ID: 18096279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
    Sewell DA; Shahabi V; Gunn GR; Pan ZK; Dominiecki ME; Paterson Y
    Cancer Res; 2004 Dec; 64(24):8821-5. PubMed ID: 15604239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
    Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
    Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization and evaluation of the immune responses elicited by a novel human papillomavirus (HPV) therapeutic vaccine: HPV 16E7-HBcAg-Hsp65 fusion protein.
    Zhou CM; Zhang GX; Ma XX
    J Virol Methods; 2014 Mar; 197():1-6. PubMed ID: 24291739
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhancement of Ad-CRT/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7.
    Rangel-Colmenero BR; Gomez-Gutierrez JG; Villatoro-Hernández J; Zavala-Flores LM; Quistián-Martínez D; Rojas-Martínez A; Arce-Mendoza AY; Guzmán-López S; Montes-de-Oca-Luna R; Saucedo-Cárdenas O
    Viral Immunol; 2014 Nov; 27(9):463-7. PubMed ID: 25216057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
    Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
    Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
    J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene.
    Gao J; Fan L; Ma W; Xiao H
    Microbiol Immunol; 2016 Sep; 60(9):626-33. PubMed ID: 27515281
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers.
    Lescaille G; Pitoiset F; Macedo R; Baillou C; Huret C; Klatzmann D; Tartour E; Lemoine FM; Bellier B
    Hum Gene Ther; 2013 May; 24(5):533-44. PubMed ID: 23521528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
    Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
    J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. One-prime multi-boost strategy immunization with recombinant DNA, adenovirus, and MVA vector vaccines expressing HPV16 L1 induces potent, sustained, and specific immune response in mice.
    Li LL; Wang HR; Zhou ZY; Luo J; Xiao XQ; Wang XL; Li JT; Zhou YB; Zeng Y
    Antiviral Res; 2016 Apr; 128():20-7. PubMed ID: 26821205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention and treatment of HPV-related cancer through a mRNA vaccine expressing APC-targeting antigen.
    Li X; Wang H; Lai W; Liao J; Mo W; Huang K; He L; Liang X; Yu Z; Xu J; Hua X; Hou F; Ding J; Jia WW; Zhang K; Wang Y
    Immunology; 2024 Jul; 172(3):375-391. PubMed ID: 38471664
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.
    Ma Y; Yang A; Peng S; Qiu J; Farmer E; Hung CF; Wu TC
    Vaccine; 2017 Jul; 35(31):3850-3858. PubMed ID: 28599791
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.
    Jemon K; Young V; Wilson M; McKee S; Ward V; Baird M; Young S; Hibma M
    PLoS One; 2013; 8(6):e66866. PubMed ID: 23799135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.